- Did you mean
- sans-cov-2
Search results - 5 results
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Vaccines Electronic Health Records Europe European Union Female Hospitalization Humans Male Retrospective Studies SARS-CoV-2 Vaccination Vaccine Efficacy Abstract: Using a common protocol across seven ...
Association between COVID-19 Primary Vaccination and Severe Disease Caused by SARS-CoV-2 Delta Variant among Hospitalized Patients: A Belgian Retrospective Cohort Study
Publication Type: Peer reviewed scientific article Authors: Queeny Robalo; Laurane De Mot; Mathil Vandromme; Nina Van Goethem; Andrea Gabrio; Pui Yan Jenny Chung; Marjan Meurisse; Belgian Collaborative Group on COVID-19 Hospital Surveillance; Lucy Catteau ...
Conceptual causal framework to assess the effect of SARS-CoV-2 variants on COVID-19 disease severity among hospitalized patients
Cuypers; Emmanuel André; Koen Blot; Herman Van Oyen Source: Archives of Public Health, Volume 79, Issue 1 (2021) Abstract: BACKGROUND: SARS-CoV-2 strains evolve continuously and accumulate mutations in ...
Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.
Humans SARS-CoV-2 vaccines Abstract: In Belgium, high-risk contacts of an infected person were offered PCR-testing irrespective of their vaccination status. We estimated vaccine effectiveness (VE) against ...
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study.
Hospitalization Humans Male SARS-CoV-2 Vaccination Vaccine Efficacy Abstract: BACKGROUND: We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/ ...